Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen

被引：0
|
作者：
Lu, D.
Krop, I.
Modi, S.
Elias, A.
LoRusso, P.
Huang, J.
Lu, M.
Girish, S.
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Colorado, Sch Med, Aurora, CO USA
[5] Wayne State Univ, Detroit, MI USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-22
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Ian E. Krop
    Shanu Modi
    Patricia M. LoRusso
    Mark Pegram
    Ellie Guardino
    Betsy Althaus
    Dan Lu
    Alexander Strasak
    Anthony Elias
    Breast Cancer Research, 18
  • [42] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
  • [43] A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+breast cancer (BC)
    Holden, S. N.
    Beeram, M.
    Krop, I. E.
    Burris, H. A., III
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Lutzker, S. G.
    Modi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [45] SEMI-MECHANISTIC POPULATION PHARMACOKINETIC MODEL OF MULTIVALENT TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS WITH METASTATIC BREAST CANCER
    Chudasama, V. L.
    Harrold, J. M.
    Schaedeli-Stark, F.
    Tibbitts, J.
    Girish, S. R.
    Gupta, M.
    Frey, N.
    Mager, D. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S89 - S89
  • [46] A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy
    Krop, I
    LoRusso, P.
    Miller, K. D.
    Modi, S.
    Yardley, D.
    Rodriguez, G.
    Agresta, S.
    Zheng, M.
    Amler, L.
    Rugo, H.
    CANCER RESEARCH, 2009, 69 (24) : 795S - 795S
  • [47] Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy
    Jain, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [49] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [50] Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer
    Jain, S.
    Nye, L.
    Santa-Maria, C.
    Bontemps, L.
    Williams, A.
    Garrett, H.
    Dammrich, E.
    Giles, F.
    Gradishar, W.
    CANCER RESEARCH, 2016, 76
12345